Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (671-680 of 706) with videos related to

Pageof 71
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
JAMA Cardiology|November 9, 2022
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care NetworkAlexander J Blood, Christopher P Cannon, William J Gordon, et al.
Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Journal of the American College of Cardiology|August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary DiseaseDaniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
American Heart Journal|June 18, 2018
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trialOrly Vardeny, Jacob A Udell, Jacob Joseph, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
JAMA|October 28, 2010
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJessica L Mega, Tabassome Simon, Jean-Philippe Collet, et al.
American Heart Journal|December 25, 2015
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarctionSean D Pokorney, Christina Radder, Phillip J Schulte, et al.
Circulation. Heart Failure|January 22, 2026
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled TrialAyodele Odutayo, Deepak L Bhatt, Vikas S Sridhar, et al.
Pageof 71

Showing results (671-680 of 706) with videos related to

Sort By:
Pageof 71
Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
JAMA Cardiology|November 9, 2022
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care NetworkAlexander J Blood, Christopher P Cannon, William J Gordon, et al.
Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Journal of the American College of Cardiology|August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary DiseaseDaniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
American Heart Journal|June 18, 2018
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trialOrly Vardeny, Jacob A Udell, Jacob Joseph, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
JAMA|October 28, 2010
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJessica L Mega, Tabassome Simon, Jean-Philippe Collet, et al.
American Heart Journal|December 25, 2015
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarctionSean D Pokorney, Christina Radder, Phillip J Schulte, et al.
Circulation. Heart Failure|January 22, 2026
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled TrialAyodele Odutayo, Deepak L Bhatt, Vikas S Sridhar, et al.
Pageof 71